Therapeutic Outcomes of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction: Experience from a Tertiary Hospital in Thailand
Article Sidebar
Main Article Content
Abstract
Objective: To study the treatment outcomes of sacubitril/valsartan in Thai patients with heart failure with reduced ejection fraction (HFrEF) in terms of heart failure hospitalization and the changes of Left Ventricular Ejection Fraction (LVEF) compared to HFrEF patients without sacubitril/valsartan use. Methods: This retrospective study compared between 111 HFrEF patients receiving sacubitril/valsartan plus standard treatment (study group) and 129 HFrEF patients with standard treatment (control group). Data were collected from January 1st, 2016 to June 30th, 2021 with a 12-month follow-up at Central Chest Institute of Thailand. The primary outcome of this study was heart failure hospitalization. Results: After a 12-month follow-up, 10 (9%) patients in the study group were hospitalized due to heart failure with a significantly lower rate than that in the control group (44 patients or 34.1%) with hazard ratio (HR) 0.20 and 95%CI 0.10-0.41 (P <0.001). After a 12-month treatment, median of LVEF improvement from baseline in the study group was 11% with interquartile range (IQR) 18.0, which was significantly higher than that in the control group at 4% (13.6) (P <0.001). Conclusion: HFrEF patients who received sacubitril/valsartan had a significantly lower rate of heart failure hospitalization and had a significantly higher LVEF improvement compare to those of patients without treatment with sacubitril/valsartan.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020; 22: 1342-56.
Murphy SP, Ibrahim NE, Januzzi JL, Jr. Heart failure with reduced ejection fraction: A review. JAMA. 2020; 324: 488-504.
Krittayaphong R, Laothavorn P, Hengrussamee K, Sanguanwong S, Kunjara-Na-Ayudhya R, Rattanasu mawong K, et al. Ten-year survival and factors associated with increased mortality in patients admitted for acute decompensated heart failure in Thailand. Singapore Med J 2020; 61: 320-6.
Maddox Thomas M, Januzzi James L, Allen Larry A, Breathett K, Butler J, Davis Leslie L, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021; 77: 772-810.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021; 42: 3599-726.
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprily sin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
McCormack PL. Sacubitril/valsartan: a review in chronic heart failure with reduced ejection fraction. Drugs 2016; 76: 387-96.
Packer M, McMurray JJV. Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet 2017; 389: 1831-40.
Rattanavipanon W, Sotananusak T, Yamaae F, Chan drsawang A, Kaewkan P, Nathisuwan S, et al. Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis. BMC Cardiovasc Disord 2021; 21: 324. doi: 10.1186/s12872-021-02145-9.
Lwanga SK, Lemeshow S. Sample size determi- nation in health studies [online]. 1991 [cited Apr 29, 2022]. Available from: apps.who.int/iris/handle/106 65/40062.
Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther 2018; 36: e12435.
Januzzi JL, Jr., Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in n-terminal pro–b-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019; 322: 1085-95.
